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Abstract
Human immunodeficiency virus type 1 (HIV-1) is completely dependent upon the Env protein to
enter cells. The virus typically replicates in activated CD4+ T cells due to viral entry requirements
for the CCR5 coreceptor and for high surface levels of the CD4 receptor. This is the case for the
transmitted virus and for most of the virus sampled in the blood. Over the course of infection, the
env gene can evolve to encode a protein with altered receptor and coreceptor usage allowing the
virus to enter alternative host cells. In about 50% of HIV-1 infections, the viral population
undergoes coreceptor switching, usually late in disease, allowing the virus to use CXCR4 to enter
a different subset of CD4+ T cells. Neurocognitive disorders occur in about 10% of infections,
also usually late in disease, but caused (ultimately) by viral replication in the brain either in CD4+
T cells or macrophage and/or microglia. Expanded host range is significantly intertwined with
pathogenesis. Identification and characterization of such HIV-1 variants may be useful for early
detection which would allow intervention to reduce viral pathogenesis in these alternative cell
types.
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Introduction
Env Protein and Gene
The Human Immunodeficiency Virus type 1 (HIV-1) env gene encodes the only surface-
expressed viral protein Env, a glycoprotein of 160 kD (gp160), which is solely required for
binding and entry into host cells. After translation, gp160 is cleaved into gp120 and gp41,
which remain non-covalently linked to form a single subunit of a trimeric “spike” on the
virion surface. The C-terminal subunit, gp41, contains a cytoplasmic domain (ultimately
inside the viral membrane), a membrane spanning domain and an extracellular domain,
which mediates the conformational change needed for fusion. The N-terminal subunit,
gp120, is completely outside the viral membrane. Although the protein has a complex fold it
can also be viewed as being linearly organized into five conserved regions (C1-C5)
interspersed with five variable regions (V1-V5). The host receptor CD4 interacts with
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residues in the conserved regions of gp120 on either side of V4, and the coreceptor CCR5
interacts both with a GPGR/Q motif at the apex of the V3 loop and at its base. The exposed
surface of the spike is dominated by two features: the variable regions of gp120, insinuating
that high variability plays and important role in extracellular interactions; and a large
number of carbohydrates that help mask the surface of the protein.
The gp120 coding domain of the env gene evolves faster (changing 1–2% per year) than any
other region of the genome [1]. Although sequence variability is generally troublesome for
maintaining required structures and functions, env variability is concentrated within discrete
regions, which protects the general architecture of the protein. Much of env variability is
driven by immune escape; however, sequence changes in gp120 can also alter interactions
with host receptors. Over the course of infection, viral populations can evolve to use the
CD4 receptor differently and to use alternative coreceptors allowing entry into alternative
host cells.
Tropism and Entry Phenotype
The Env protein is an entry machine, built to bind to CD4, undergo a series of
conformational changes, fuse the cell and viral membranes, and deliver the viral core to the
cytoplasm of the cell. Given that most transmissions occur across mucosal surfaces,
persistent replication takes place in lymphoid tissues, and disease manifestations are
apparent in many tissues/organs, it is clear that the virus has ample opportunity to encounter
many different cell types. Much of the research on the virus side of viral pathogenesis is
focused on the Env protein and its role in entry. In order to understand this, we need to be
able to accurately identify and characterize variants able to infect alternative target cells (i.e.
expanded host range), including when and where these variants first occur, when they
become prevalent and how this affects pathogenesis. More mechanistically, we need to
know how viruses with expanded host range differ from the rest of the viral population in
terms of receptor use, coreceptor use, physical changes in Env and the consequences of
these changes.
HIV-1 Comes In (At Least) Three Colors, Not Two
For 25 years the majority view of HIV-1 has been that it comes in two colors, or rather entry
phenotypes. The initial dichotomy was based on the observation that only some HIV-1
isolates could grow in transformed CD4+ T cell lines. Furthermore, since HIV-1 Env protein
mediates fusion without the need for reduced pH this allows infected cells, with the Env
protein on the surface of the cell, to fuse with uninfected cells creating syncytia and giving
the appearance of a pathogenic virus. The isolates that did not grow in the transformed cell
lines could not cause syncytia, thus setting up the early classification of syncytium-inducing
(SI) and nonsyncytium-inducing (NSI) viruses [2]. Some NSI viruses could also infect
macrophages. The NSI and SI designations have changed with the discovery of the
coreceptor, with SI being equal to CXCR4-using (X4) and with NSI being equal to CCR5-
using (R5), and all of this can be traced to the fact that most transformed CD4+ T cell lines
do not express CCR5 [3]. Thus, the legacy groupings are NSI/R5/macrophage-tropic and SI/
X4 viruses.
However, these two groups fail to capture the important concept that only a small (but
important) fraction of R5 viruses are able to infect macrophages, necessitating the use of
three groupings: R5 T cell-tropic, R5 macrophage-tropic, and X4. The distinction between T
cell-tropic and macrophage-tropic R5 viruses is not a small point, because gaining the ability
to infect macrophages represents an important but poorly understood part of HIV-1
pathogenesis. The salient features of these three groups are described in the following
section then discussed in greater detail below in the context of evolution over the disease
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course of an infected person. Figure 1 provides a framework for the main topics covered in
this review.
R5 T cell-tropic Virus
HIV-1 spends most of its time replicating in activated CD4+ T cells [4–6]. Activated T cells
are activated in the context of the immune response, but also are metabolically active
making viral replication more efficient. These cells are infected by the form of the virus that
is transmitted in the vast majority of cases, that persists in the host for years, that most often
causes immunodeficiency, and that is sufficient to account for most of what we think of as
the HIV-1 epidemic. The entry phenotype of this virus is clearly defined by the requirement
for CCR5 to allow entry and also the need for high levels of CD4 on the surface of the cell
as found on activated CD4+ T cells [7, 8].
R5 Macrophage-Tropic Virus
Some isolates of HIV-1 that can infect CD4+ T cells can also infect macrophages (i.e. are
M-tropic). A commonly used viral clone, Ba-L, was the first M-tropic virus isolate, in this
case from macrophages recovered from a bronchial/alveolar lavage [9]. Although M-tropic
viruses are most often found in the central nervous system (CNS) [10–12], they have also
been observed in the blood [10] and other compartments [10, 12]. In one case, the M-tropic
virus in the blood was not derived from the CNS, suggesting alternative tissue sites where
macrophage-tropic viruses can evolve beyond the CNS [13•].
X4 T Cell-Tropic Virus
As noted above, the evolution of variants that can use CXCR4 is a distinctive and consistent
feature of the viral population in a significant fraction of those infected with the virus. There
are continuing discussions as to whether these variants are selected against at the time of
transmission, whether they can survive only in an immunodeficient host, whether they
contribute to or are a marker for more rapid disease progression, and whether different
subtypes have a different propensity to evolve these variants. Thus, while we know a great
deal about the evolution of these variants and their properties, we cannot yet place them with
confidence in the context of viral pathogenesis.
env Gene Evolution and Phenotypic Variation
The Transmitted Virus
Much attention is now being paid to the nature of the transmitted virus and, in particular, the
properties of the Env protein associated with transmission. At one end of the debate is the
idea that the transmitted virus is the random but lucky winner of a group of viruses
deposited at a mucosal site. At the other end is the idea that only viruses with certain
properties are transmitted; in this case, information about the transmitted virus would
provide insight into the process of transmission and could be important to the development
of prevention strategies such as vaccines and microbicides. Early studies of the virus present
in people with acute infection demonstrated that there is a significant genetic bottleneck
associated with sexual transmission. However, an important conceptual insight came with
the understanding that, in a majority of cases, infection is initiated with a single variant [14•,
15].
There is still uncertainty about whether multiple variants are transmitted but a single variant
is detected systemically, or if a single variant establishes the initial infection at the site of
transmission and is the progenitor to all of the virus in the body. Sampling of the blood
suggests a single variant is transmitted [16]; however, it is possible that there are abortive
infections at the mucosa that do not contribute to the systemic viral population. If true, then
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there should be examples of abortive infections without systemic infection. In such a
scenario, the level of viral replication must be low, since we do not observe people who are
seropositive for HIV-1 but not infected (in contrast to HSV-2, for example, which induces
seropositivity after a local infection in the mucosa). A subset of people are infected with
multiple variants (i.e. two or more viruses from the same donor), which may be related to
the route of infection or other cofactors that affect the frequency of transmission [17]. An
important question is: does the extra genetic diversity associated with the transmission of
multiple variants affect the rate of disease progression, a phenomenon that has been
associated with dual infection from two sources [18]?
The severe transmission bottleneck begs the question of whether there is something
consistently special about the single transmitted virus. If there is something special, then it is
possible that this variant is selected at the donor site of transmission, during the transmission
process, or after transmission. There can be local populations of virus at the donor site, i.e.
compartmentalized virus in the seminal tract or the vaginal/cervix area (see [19] as an
example), although the biological properties of these compartmentalized viruses have not
been explored. At present, there is no evidence that these compartmentalized variants are
favored in transmission.
Several studies have observed that the transmitted virus is underglycosylated [20, 21], and in
our own work we have found that the virus in acutely infected men is more
underglycosylated than the virus in acutely infected women (Ping et al., manuscript in
preparation). This observation suggests that there is selective pressure in the transmission
process itself, i.e. female-to-male transmission favors underglycosylated Env proteins. We
observed a similar trend in intrapartum transmission where infants are also exposed to
cervico-vaginal mucus [22]. Finally, it has been proposed that there is selective pressure
after transmission either in the form of neutralization sensitive virus that replicates more
quickly [21] or virus that binds to α4β7 integrin to promote attachment to cells in the
mucosa and the gut-associated lymphoid tissue (GALT) [23].
To date, these hypotheses have been explored with a relatively small number of virus
isolates and the role of these features in transmission will likely be examined in greater
detail soon. It is worth repeating that even using a deep sequencing approach it has not been
possible to find heterogeneity in the blood beyond the transmitted virus [16]. Thus, if there
is selection in the new host among multiply transmitted variants, it must take place
completely within tissue that is not releasing significant amounts of virus into the blood.
Early Evolution of the env Gene
The selective pressure on the env gene that is unique among viral gene products is that the
Env protein is the only target of neutralizing antibodies. Thus, the host antibody response
drives evolution with the initial autologous response to the transmitted virus and with
sequential responses to the escape variants [24]. Important targets for the host antibodies are
in the variable loops V1, V2, V4, and V5; to a certain extent this conclusion is inferred
based on the extreme variability of these regions, since autologous responses to Env have
been mapped in only a limited number of cases [25]. In addition, env is also under selection
from cell-mediated immunity and this also results in escape mutations.
Because mutations are random, it is not that the regions encoding the variable loops are
preferentially mutated, rather a greater fraction of the mutations in these regions give viable
protein products that can be tested for escape. Evolution to avoid antibodies takes place on
at least three levels. First, the Env protein is in a conformation that makes it neutralization
resistant relative to other conformations the protein can assume. Amino acid changes
between V1 and V2 (and perhaps elsewhere) control these conformation states and can
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expose the V3 loop and the coreceptor binding site to neutralization [26–28]. Second, escape
occurs through point mutations that affect immune recognition [25]. In this aspect, the
variable loops seem to serve the role of decoy, i.e. targets for host antibodies that easily
evolve to allow escape. Third, the heavily glycosylated surface of Env can shield the protein
surface from exposure to antibodies [29, 30]. One feature of these variable regions that may
facilitate mutations is the concentration of specific trinucleotides that could enhance
duplications or deletions through mispairing during viral DNA synthesis. In addition, these
trinucleotides include the codons needed to encode N-linked glycosylation sites [31, 32].
Thus, HIV-1 Env mediates an intricate and delicate balance between the function of cell
entry and evasion of antibody selection.
Evolution of X4 Variants
X4 virus was initially perceived as a more pathogenic variant that appeared late in disease.
This idea came from the observation that viruses isolated from some late stage subjects
could grow in transformed T cell lines and cause syncytia (SI viruses), a striking feature of
the culture that gave the impression of pathogenesis. However, these viruses are not
necessarily more pathogenic; viruses that use CCR5 (formerly NSI viruses) can grow in
transformed T cell lines and cause syncytia if CCR5 is expressed.
The ability to replicate in transformed T cell lines did provide a useful assay for detecting
X4 variants, which demonstrated the increased presence of X4 virus with decreasing CD4+
T cell count in cohorts of infected people [33]. These results were subsequently confirmed
by entry assays that distinguished between R5 and X4 viruses [34]. There are two important
questions about X4 viruses that remain unresolved. First, do X4 viruses cause more rapid
disease progression or are they just a marker for increased immunodeficiency? The second
question has to do with viruses that can use both CCR5 and CXCR4 to enter cells, known as
dual-tropic viruses. Do these viruses continue to use CCR5 in vivo with dual tropism an
important part of their biology, or is the residual CCR5 usage a mere vestige of ancestry and
only CXCR4 usage is biologically relevant? Most X4 isolates are dual tropic, so this issue is
relevant to our understanding of a majority of X4 variants. An unexplained observation is
that X4 viruses appear to be more common in people who have been treated, but failed,
therapy – although this is in part explained by low nadir CD4+ T cell counts prior to
initiating therapy [35].
Evolution of the ability to infect using CXCR4 should expand the potential target cells
available to X4 viruses. It seems unlikely that X4 variants would evolve to infect the same
cells as R5 viruses; thus, the expectation is that CD4+ T cells expressing CXCR4, but not
CCR5, are the targets of X4 viruses. This reasoning is consistent with the observations that
memory CD4+ T cells express CCR5 and are the predominant cell infected [4–6], while
naïve cells express very little CCR5 but both cell types express CXCR4 [36, 37]. R5 and X4
viruses can be separately cultured from populations of memory and naïve T cells,
respectively [38]. However, the cell type where X4 variants first appear and if they compete
with or outgrow R5 viruses is still difficult to assess [39, 40]. There is evidence that when
both R5 and X4 viruses are present in a person, they are both replicating in short-lived cells,
presumably activated CD4+ T cells [41].
Even before the HIV-1 coreceptors had been identified, it was known that sequence changes
in the V3 loop were major determinants defining the properties of late stage viruses [42].
The most consistent observation of sequence evolution is the appearance of basic amino acid
substitutions (Lys and Arg), at positions 11, 24, and 25 of the 35-amino-acid-long V3 loop
[43, 44]. Overall, diversity is higher in V3 when these basic amino acid substitutions are
present, indicating that these substitutions are part of a more complex evolutionary pathway.
These basic amino acid substitutions and increased diversity have made it possible to
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develop bioinformatic tools that predict coreceptor usage of viruses based on V3 loop
sequence [45, 46].
Evolution to use CXCR4 likely includes more than just sequence changes in V3. Using a
bioinformatics approach, it has been possible to identify sequence changes outside of V3
that are statistically linked to changes within V3, with the strongest association at position
440 in the Env protein, a position lying directly under the V3 loop in the gp120 crystal
structure [47]. Molecular recombinants have been used to demonstrate the contribution of
other regions of Env to entry phenotype [48]. However, the interpretation of these results is
complicated for several reasons. First, the ability to enter cells using CXCR4 ranges on a
continuous scale from nil to completely specific, meaning that in between are viruses that
use both CCR5 and CXCR4 with every ratio of efficiency. Does a little CXCR4 tropism
indicate the initial evolution of an X4 virus or do highly sensitive entry assays identify
"sloppy" viruses that have some capacity to use CXCR4 but not in a biologically meaningful
way? By extension, what is the significance of mutations that confer only a low level of
CXCR4 tropism? Seeing mutations accumulate over time in Env genes from strongly X4
viruses provides the clearest evidence that these sequence changes are relevant to the
coreceptor switch. However, we have too few examples of X4 viruses to create robust
analyses to find the sets of mutations that are likely to define a number of evolutionary
pathways.
An important, but difficult, question that speaks to the mechanism of X4 evolution is the
propensity of viruses from different subtypes to undergo the coreceptor switch. A
provocative observation was that X4 viruses were present in some subjects with AIDS but
not others and this correlated with the subtype of the virus [49]. We have the most data for
people infected with subtype B, where about 50% of those infected develop an X4 virus
[33]. Subtype D, which is closely related to subtype B, appears to have an even greater
propensity to evolve X4 variants [50]. Conversely, subtype C seems less inclined (but not
unable) to evolve X4 variants [49]. In general, X4 variants appear late in disease. If we
assume the host can suppress the replication of these variants until the time of
immunodeficiency, and we assume different infected populations do not vary in a way that
enhances or suppresses the ability of these viruses to evolve, then what remains is
differences in the virus. Since all of these viruses can evolve X4 variants, perhaps it is the
evolutionary distance the virus has to travel that defines the differences, i.e. subtype D
viruses have the shortest distance followed by B then C.
Additional insights have been gained from studying R5 and X4 viruses in the macaque
animal model. R5 Simian immunodeficiency virus (SIV) isolates only rarely undergo
coreceptor switching [51]. However, there are several examples where SIV engineered to
have an HIV-1 env gene, known as a SHIV, undergoes a coreceptor switch from R5 to X4
[52, 53]. The switch takes place in animals that are rapid progressors due to a poor initial
immune response. The initial evolution of the X4 variant has been tracked to secondary
lymphoid tissue [54], which is similar to an observation made in the humanized mouse
model [26]. In animals infected with an X4 variant, there is rapid depletion of naïve CD4+ T
cells followed by loss of memory cells, consistent with the idea that X4 viruses
preferentially target a cell type different from R5 viruses [55, 56].
Evolution of M-tropic viruses
"Beauty is in the eye of the beholder" (a paraphrase of Plato). The definition of a
macrophage-tropic virus is problematic. Monocyte-derived macrophages (MDM) from
different donors can be very different in their ability to allow entry of a virus. Thus, a virus
that appears macrophage-tropic on one preparation of MDMs may not appear to be
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macrophage-tropic on another preparation. Also, viruses have a continuum of entry
phenotypes making it hard to draw a line that demarcates macrophage- and nonmacrophage-
tropic viruses. The difficulty, as with defining X4 viruses, is deciding when the entry
phenotype measured in the laboratory represents a biologically meaningful property for the
virus in vivo. A major challenge for this field is accurately placing the phenotype of the
ability to infect MDMs into the proper biological context.
Macrophage-tropic (M-tropic) viruses have most often been reported in the brain of HIV-
infected individuals with neurocognitive disorders [11, 57, 58] and this is one place where
the evolution of M-tropic virus is likely to play a direct role in viral pathogenesis. M-tropic
viruses can also be detected in the cerebrospinal fluid (CSF) and, in one case, it was possible
to detect this lineage before diagnosis of neurocognitive disorder [13•]. In the brain, M-
tropic viruses may be replicating in perivascular macrophages or microglia, which are
macrophage-like cells residing in the parenchyma of the brain. In the absence of pleocytosis,
T cells are uncommon in the CNS; however, pleocytosis is associated with replication of R5
T cell-tropic virus within the CNS [13•]. An important tool in assessing localized viral
replication is that viral populations in the CNS can be genetically diverse and genetically
distinct from populations in the blood (i.e. compartmentalized) [59–62]. However, not all
potential compartments (i.e. compartments with high concentrations of macrophage or
macrophage-like cells) have been systematically explored (discussed below), and
compartmentalized M-tropic virus has been detected in the semen of one person [10]. As we
develop a better understanding of how to define macrophage-tropic viruses it will be
worthwhile to explore other compartments with known HIV-associated pathogenesis (e.g.
liver).
Currently, M-tropic variants are isolated from autopsy brain tissue or from the CSF, which
can be used to sample virus longitudinally from living patients over the course of infection
and disease. Later during infection, M-tropic virus may become detectable as a minor
variant in the blood [63•, 64], though the anatomical origins of these variants have not been
established. M-tropism has been associated predominantly with the ability to use low cell
surface densities of CD4, but also with changes in CCR5 usage (currently under dispute with
some groups observing ability to use lower levels of CCR5 [65, 66] and other observing no
change in CCR5 usage [67, 68], enhanced fusogenicity [69], sensitivity to antibody
neutralization [70–72] and an altered – specifically “open” – conformation (which may be a
precursor for changes in both CD4 usage and neutralization sensitivity [65, 73•].
As noted above, the surrogate test for M-tropism in vivo is the ability of virus to infect
MDM. An alternative method is to use cell lines engineered to have different levels of CD4
and measure the dependence of infectivity on CD4 density. The latest iteration of this
approach is a novel cell line, Affinofile cells, developed by Benhur Lee [74], which have
independently inducible CD4 and CCR5 expression. Affinofile cells are highly consistent in
receptor expression and resulting infectivity; receptors can be induced to a wide range of
densities, including normal physiological levels found on macrophages and T cells and
beyond (allowing titration of receptor/coreceptor usage). Most importantly, these cells allow
isolation of the entry requirement variables without potentially confounding post-entry
factors.
Although there are likely multiple adaptations required to infect macrophages, M-tropic
variants are largely defined by their ability to infect cells expressing low levels of CD4 [67],
which reflects the relatively low CD4 density on the surface of macrophages as compared to
activated memory T cells [37]. The search for sequence changes in gp120 to allow binding
and entry into cells with lower densities of CD4 has focused on regions directly involved in
receptor/coreceptor interactions: around the CD4 binding residues [57, 58, 70, 75] and
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around the V3 loop (and coreceptor binding residues) of gp120 [12, 76]. Others, however,
have proposed that mutations in the V1-V2 loop [77, 78] or in gp41 [66] can induce
significant changes in gp120 conformation, which may cause greater exposure of receptor/
coreceptor binding sites. Although most M-tropic variants are R5 viruses, there is evidence
for the existence of M-tropic X4 virus [79, 80], though their prevalence and role in
pathogenesis is not yet clear.
Defining genetic determinants of macrophage tropism is essential to being able to screen for
these viruses in mixtures and in large numbers of biological samples, as the totality of the
effort required to identify these viruses by entry phenotype is cumbersome and quickly
becomes limiting. Unfortunately, there is little overlap in the mutations identified by
different groups to date (see Table 1). This discord could be explained by the time at which
viruses were isolated (before appearance of neurocognitive symptoms or late in disease,
including autopsy samples); a potentially diverse number of evolutionary pathways to reach
M-tropism (open conformation to increase binding site exposure, greater affinity for
receptor/coreceptor within the binding site, increased fusion efficiency to counteract the loss
in infectivity wrought by low CD4 densities, etc.); or by different changes within a region of
gp120 that result in a similar phenotype, but do not align precisely in sequence analysis. If
essential or signature mutations can be identified for M-tropism, then HIV-infected
individuals could be screened for M-tropic variants – by deep sequencing, if necessary, to
deal with mixtures of M-tropic and T-tropic variants – to inform care and potentially reduce
neurocognitive pathogenesis by early intervention.
Infection of Monocytes
Given the clear evidence for infection of macrophages in vivo there is also interest in
whether the precursors of macrophages, i.e. monocytes, can be infected by HIV-1.
Monocytes are a diverse cell population that can be divided into three subsets - classical,
intermediate and nonclassical. These subsets differ in size and shape [81, 82], expression of
surface markers [83, 84], susceptibility to HIV infection [83, 85], cytokine production [81]
and role in the immune system [81, 82]. After being produced from common myeloid
progenitor cells in the bone marrow [86], they enter the blood as classical monocytes and
can then differentiate into intermediate and then into nonclassical monocytes [87]. The three
monocyte subsets are most easily separated by expression of CD14 and CD16, with classical
monocytes expressing high levels of CD14 and lacking CD16 (CD14++, CD16−),
intermediate monocytes expressing high levels of CD14 and low levels of CD16 (CD14++,
CD16+) and nonclassical monocytes expressing low levels of CD14 and high levels of CD16
(CD14+, CD16++)[84, 87]. In healthy donors, approximately 85% of monocytes fall into the
classical subset, 5% are intermediate and 10% are nonclassical [84].
Multiple in vitro studies have shown that freshly isolated monocytes are not productively
infected by HIV-1, but can be productively infected after they are allowed to differentiate
for at least one day and are increasingly susceptible to infection as they differentiate into
MDMs [88, 89]. The resistance of monocytes to HIV-1 infection is likely due to blocks at
multiple points in the virus life cycle. A block at entry could occur if densities of the
receptor (CD4) or coreceptors (CCR5 or CXCR4) were very low on monocytes. This is
probably not the case for CD4, which is expressed at appreciable levels on most monocytes
[83], albeit at much lower levels than on T cells [37]. In contrast, CCR5 and/or CXCR4 are
only expressed by a minority of monocytes and are expressed at low levels [83]. It has been
observed that CCR5 density on monocytes and susceptibly to HIV-1 infection are correlated
with the amount of time that monocytes spend in culture, thus fueling speculation that CCR5
levels are too low to facilitate virus entry into freshly isolated monocytes [88]. Multiple
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blocks to reverse transcription [90, 91] and transcription of the proviral genome [92] have
been observed in monocytes.
An alternative model is that HIV-1 infection of monocytes is not blocked, but rather the
mechanisms described above simply slow the virus lifecycle [93]. Considering that
monocytes persist in the blood for only a few days [94] before dying or migrating into
tissues and differentiating into DCs or macrophage, this alternative model suggests that
infected monocytes are likely to differentiate before producing virus. While many questions
remain about putative blocks to monocyte infection, it appears clear that HIV replication in
monocytes is unlikely to contribute substantially to viral loads. However, given the ability of
monocytes to enter tissues, infected monocytes could provide an important mechanism to
disseminate virus to sites where independent replicating populations could be established.
One limitation of most of these in vitro studies is that they have not separately examined
infection of the three monocyte subsets. Since approximately 85% of monocytes in the
blood are of the classical subset [84], most studies to date have focused on infection of this
subset. This is significant given that classical monocytes are the most undifferentiated
subset, contain the lowest percentage of CCR5+ cells and are the least susceptible to
infection in vitro [83]. Given the extensive evidence that differentiation increases
susceptibility to infection of monocytes [88, 89], and the observation that monocytes
expressing CD16 are more susceptible to infection [83], intermediate and nonclassical
monocytes should be more susceptible to infection than classical monocytes.
In contrast to the in vitro studies examining whether HIV-1 can productively infect
monocytes, multiple studies have isolated monocytes that contain HIV-1 DNA [63•, 95] and
replication competent virus [96•], thus indicating that monocytes are infected in vivo.
Analysis of env sequences isolated from these cells showed that monocytes can harbor
viruses that appear distinct from those in the blood [95]. Further phenotypic analysis of these
viruses revealed that they were all capable of using CCR5 as their coreceptor. Some were
also able to use alternative coreceptors (CXCR4, CCR1, CCR3 and GPR15) and, while all
of the monocyte derived viruses were capable of replicating in macrophage in vitro, only a
subset of them could replicate in T cells [63•]. Given the short half-life of monocytes in the
blood and the fact that the monocytes most susceptible to infection are likely to be near the
end of this period, it is difficult to understand how a stable, diverse population of monocyte-
tropic viruses could be maintained. One possibility is that monocytes are being infected by
macrophage-tropic viruses replicating in tissue macrophage [63•]. Reports of monocytes
being infected in individuals who are on otherwise suppressive therapy also present a
challenge to understanding the virus life cycle in this enigmatic cell type.
Use of Alternative Co-receptors
People who carry two alleles of the delta32 deletion of the CCR5 gene are largely resistant
to infection by HIV-1, consistent with the vast majority of infections being initiated with an
R5 virus. In some isolates it is possible to show promiscuity in the ability to use different
coreceptors in entry assays, but the biological significance of these observations is unknown,
i.e. it is not clear if these alternative coreceptors are actually used in vivo. However, the
potential to use an alternative coreceptor has clearly been demonstrated in the case of SIVsm
infection of sooty mangabeys, which can also have an inactivating mutation in the CCR5
gene. Infection by SIVsm in these animals cannot use CCR5 but may use GPR15 and/or
CXCR6 as an alternative coreceptor [97].
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HIV infection of CD4–negative cells
It has long been thought that HIV-1 tropism is primarily limited by expression of CD4 and
CXCR4 or CCR5; thus it is surprising that multiple studies have reported that HIV-1 can
infect cells lacking these receptors [98–102]. The fact that most primary isolates require
CD4 to infect [103] suggests that evolving the ability to be CD4-independent comes with an
evolutionary cost. This cost could be in the form of increased sensitivity to neutralization
[99, 103] or the ability to enter cells that do not support efficient viral replication, but could
impact the range of viral pathogenesis. A possible example of CD4-indepence evolving in
vivo is renal-tropic HIV which is thought to infect kidney epithelial cells. These cells lack
CD4 [102, 104], CCR5 and CXCR4 [104]. Infection of these CD4-negative cells is
suggested by studies showing that patients with HIV-associated renal diseases often have
kidney epithelial cells containing HIV-1 mRNA [105] and DNA [102]. Surprisingly, a study
of two patients with HIV-associated nephropathy found that that viral DNA isolated from
kidney epithelial cells forms a lineage that is evolutionarily separate from that of viral DNA
in the blood [102]. This result suggests that there is an independent population of viruses
infecting kidney epithelial cells; however, this conclusion was obtained with a small number
of kidney-derived gp120 sequences and additional studies are need to confirm this finding.
Since many viruses have evolved the ability to enter their hosts using a single receptor, it is
curious that HIV-1 requires two receptors (CD4 and CCR5 or CXCR4), thus fueling
speculation that this dual receptors system confers an evolutionary advantage. One
possibility is that having CD4 as a receptor allows the Env protein to be in one conformation
prior to binding and a different conformation (and immunogenic state) after binding when
the fusion mechanisms of Env become active. It is clear that the regions of Env that interact
with CD4 are distinct from those that interact with CCR5 and also distinct from the actual
fusion machinery. Thus it is possible to imagine a form of Env that is CD4-independent, i.e.
in the alternative or bound conformation that allows interaction with CCR5 and subsequent
fusion. It has been possible to select for such variants in culture; in vitro studies have shown
that HIV-1 can evolve CD4-independence [98, 100, 101]. The exact nature of these viruses
is still being worked out since there is an important distinction between viruses that can use
very low levels of CD4 versus those that are truly CD4 independent. The mutations that
confer CD4 independence include changes in C2, C3 and V3 that are thought to alter
coreceptor binding [98] and changes in gp41 with unknown effects on coreceptor binding
[66]. This concept of alternative conformations has also carried over into the idea that late in
disease there may be relaxed antibody selection on Env allowing it to evolve an alternative
conformation for the purpose of using CD4 more efficiently; the corollary of this model is
that the alternative conformation may also potentiate the evolution to use CXCR4 or the
evolution to use low levels of CD4 and in this way expand the host range, and the
pathogenic potential, of HIV-1.
Conclusions
HIV-1 env mutates rapidly under evolutionary pressure from multiple sources such that the
encoded Env protein displays a delicate balance between continual immune evasion and
retention of the vital function of host cell entry. There are at least three different colors or
host range variants of HIV-1 as determined by the Env protein. The first is the R5 T cell-
tropic virus, which is typically the single transmitted virus and also the virus most
commonly found throughout chronic infection. The second is the R5 macrophage-tropic
virus, which is most often reported in the CNS of people with HIV-associated
neurocognitive disorders – although macrophage-tropic viruses with a non-CNS (and
unknown) origin have also been detected. The third is the X4 virus, which frequently
emerges in late disease and is associated with advanced immunodeficiency. While the
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mechanisms and evolutionary “motivations” are not fully clear, evolving altered receptor
and coreceptor usage allows the virus to infect new cell types with potentially serious
pathogenic consequences.
Acknowledgments
We would like to thank the NIH for funding that supports our ongoing research in this field. We also apologize to
our colleagues whose work we did not cite due to editorial limitations.
References
1. Leitner T, Kumar S, Albert J. Tempo and mode of nucleotide substitutions in gag and env gene
fragments in human immunodeficiency virus type 1 populations with a known transmission history.
J Virol. 1997; 71:4761–4770. [PubMed: 9151870]
2. Asjo B, Morfeldt-Manson L, Albert J, et al. Replicative capacity of human immunodeficiency virus
from patients with varying severity of HIV infection. Lancet. 1986; 2:660–662. [PubMed: 2429124]
3. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry,
tropism, and disease. Annu Rev Immunol. 1999; 17:657–700. [PubMed: 10358771]
4. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIVspecific CD4+ T cells.
Nature. 2002; 417:95–98. [PubMed: 11986671]
5. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency
virus (HIV) in vivo: implications for HIV pathogenesis. J Virol. 2004; 78:1160–1168. [PubMed:
14722271]
6. Sleasman JW, Aleixo LF, Morton A, et al. CD4+ memory T cells are the predominant population of
HIV-1-infected lymphocytes in neonates and children. AIDS. 1996; 10:1477–1484. [PubMed:
8931781]
7. Alexander M, Lynch R, Mulenga J, et al. Donor and recipient envs from heterosexual human
immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J Virol.
2010; 84:4100–4104. [PubMed: 20147398]
8. Isaacman-Beck J, Hermann EA, Yi Y, et al. Heterosexual transmission of human immunodeficiency
virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy
of CCR5 utilization. J Virol. 2009; 83:8208–8220. [PubMed: 19515785]
9. Gartner S, Markovits P, Markovitz DM, et al. The role of mononuclear phagocytes in HTLV-III
LAV infection. Science. 1986; 233:215–219. [PubMed: 3014648]
10. Brown RJP, Peters PJ, Caron C, et al. Intercompartmental Recombination of HIV-1 Contributes to
env Intrahost Diversity and Modulates Viral Tropism and Sensitivity to Entry Inhibitors. J Virol.
2011; 85:6024–6037. [PubMed: 21471230]
11. Peters PJ, Sullivan WM, Duenas-Decamp MJ, et al. Non-macrophage-tropic human
immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen:
implications for transmission and pathogenesis. J Virol. 2006; 80:6324–6332. [PubMed:
16775320]
12. Thomas ER, Dunfee RL, Stanton J, et al. Macrophage entry mediated by HIV Envs from brain and
lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of
fusion. Virology. 2007; 360:105–119. [PubMed: 17084877]
13. Schnell G, Joseph S, Spudich SS, et al. Two classes of viral encephalitis contribute to the
development of HIV-1-associated dementia. PLoS Pathog. In press. . This paper demonstrates the
production of macrophage-tropic virus from a long-lived cell in a subset of subjects with HIV-
associated dementia.
14. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted
and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;
105:7552–7557. [PubMed: 18490657] . This paper demonstrates that in most transmissions of
HIV-1, the systemic infection is derived from a single viral genome.
Arrildt et al. Page 11













15. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with
human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted
variants. J Virol. 2009; 83:3556–3567. [PubMed: 19193811]
16. Fischer W, Ganusov VV, Giorgi EE, et al. Transmission of single HIV-1 genomes and dynamics of
early immune escape revealed by ultra-deep sequencing. PLoS One. 2010; 5:e12303. [PubMed:
20808830]
17. Li H, Bar KJ, Wang S, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with
Men. PLoS Pathog. 2010; 6:e1000890. [PubMed: 20485520]
18. Gottlieb GS, Nickle DC, Jensen MA, et al. Dual HIV-1 infection associated with rapid disease
progression. Lancet. 2004; 363:619–622. [PubMed: 14987889]
19. Anderson JA, Ping LH, Dibben O, et al. HIV-1 Populations in Semen Arise through Multiple
Mechanisms. PLoS Pathog. 2010; 6:e1001053. [PubMed: 20808902]
20. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope
glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain
genetic subtypes and may impact viral RNA levels. J Virol. 2005; 79:6528–6531. [PubMed:
15858037]
21. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive
HIV-1 after heterosexual transmission. Science. 2004; 303:2019–2022. [PubMed: 15044802]
22. Russell ES, Kwiek JJ, Keys J, et al. The Genetic Bottleneck in Vertical Transmission of Subtype C
HIV-1 Is Not Driven by Selection of Especially Neutralization Resistant Virus from the Maternal
Viral Population. J Virol. 2011:8253–8262. [PubMed: 21593171]
23. Nawaz F, Cicala C, Van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes
alphabeta-reactivity, revealing alphabetaCD4+ T cells as key targets in mucosal transmission.
PLoS Pathog. 2011; 7:e1001301. [PubMed: 21383973]
24. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody
response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100:4144–4149. [PubMed:
12644702]
25. Moore PL, Gray ES, Morris L. Specificity of the autologous neutralizing antibody response. Curr
Opin HIV AIDS. 2009; 4:358–363. [PubMed: 20048698]
26. Ince WL, Zhang L, Jiang Q, et al. Evolution of the HIV-1 env gene in the Rag2−/− gammaC−/−
humanized mouse model. J Virol. 2010; 84:2740–2752. [PubMed: 20042504]
27. Pugach P, Kuhmann SE, Taylor J, et al. The prolonged culture of human immunodeficiency virus
type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology.
2004; 321:8–22. [PubMed: 15033560]
28. Shibata J, Yoshimura K, Honda A, et al. Impact of V2 mutations on escape from a potent
neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human
immunodeficiency virus type 1 isolate. J Virol. 2007; 81:3757–3768. [PubMed: 17251298]
29. Binley JM, Ban YE, Crooks ET, et al. Role of complex carbohydrates in human immunodeficiency
virus type 1 infection and resistance to antibody neutralization. J Virol. 2010; 84:5637–5655.
[PubMed: 20335257]
30. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;
422:307–312. [PubMed: 12646921]
31. Bosch ML, Andeweg AC, Schipper R, Kenter M. Insertion of N-linked glycosylation sites in the
variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT
triplet reiteration. J Virol. 1994; 68:7566–7569. [PubMed: 7933144]
32. Kitrinos KM, Hoffman NG, Nelson JA, Swanstrom R. Turnover of env variable region 1 and 2
genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol.
2003; 77:6811–6822. [PubMed: 12768001]
33. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate
of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993; 118:681–688. [PubMed:
8096374]
34. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease
progression in HIV-1--infected individuals. J Exp Med. 1997; 185:621–628. [PubMed: 9034141]
Arrildt et al. Page 12













35. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-
treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006; 194:926–930.
[PubMed: 16960780]
36. Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially
expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997; 94:1925–
1930. [PubMed: 9050881]
37. Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5, and CXCR4 levels on
lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived
macrophages. Proc Natl Acad Sci U S A. 1999; 96:5215–5220. [PubMed: 10220446]
38. Blaak H, van't Wout AB, Brouwer M, et al. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells
is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T
cell decline. Proc Natl Acad Sci U S A. 2000; 97:1269–1274. [PubMed: 10655520]
39. Heeregrave EJ, Geels MJ, Brenchley JM, et al. Lack of in vivo compartmentalization among
HIV-1 infected naive and memory CD4+ T cell subsets. Virology. 2009; 393:24–32. [PubMed:
19698967]
40. van Rij RP, Blaak H, Visser JA, et al. Differential coreceptor expression allows for independent
evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest. 2000;
106:1569. [PubMed: 11120764]
41. Ince WL, Harrington PR, Schnell GL, et al. Major coexisting human immunodeficiency virus type
1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates
and show little evidence of genetic compartmentalization. J Virol. 2009; 83:4068–4080. [PubMed:
19211740]
42. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary
determinant of cell tropism in HIV-1. Science. 1991; 253:71–74. [PubMed: 1905842]
43. de Jong JJ, Goudsmit J, Keulen W, et al. Human immunodeficiency virus type1 clones chimeric
for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol. 1992;
66:757–765. [PubMed: 1731110]
44. Milich L, Margolin BH, Swanstrom R. Patterns of amino acid variability in NSI-like and SI-like
V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein.
Virology. 1997; 239:108–118. [PubMed: 9426451]
45. Jensen MA, Li FS, van 't Wout AB, et al. Improved coreceptor usage prediction and genotypic
monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env
V3 loop sequences. J Virol. 2003; 77:13376–13388. [PubMed: 14645592]
46. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human
immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks.
Virology. 2001; 288:51–62. [PubMed: 11543657]
47. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, et al. Variability in the human immunodeficiency
virus type 1 gp120 Env protein linked to phenotypeassociated changes in the V3 loop. J Virol.
2002; 76:3852–3864. [PubMed: 11907225]
48. Huang W, Toma J, Fransen S, et al. Coreceptor tropism can be influenced by amino acid
substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1
envelope protein. J Virol. 2008; 82:5584–5593. [PubMed: 18353956]
49. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between
genetic subtypes of HIV-1. Virology. 1998; 241:181–188. [PubMed: 9499793]
50. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type
1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral
populations. J Virol. 2007; 81:7885–7893. [PubMed: 17507467]
51. Sina ST, Ren W, Cheng-Mayer C. Coreceptor use in nonhuman primate models of HIV infection. J
Transl Med. 2011; 9(Suppl 1):S7. [PubMed: 21284906]
52. Ho SH, Tasca S, Shek L, et al. Coreceptor switch in R5-tropic simian/human immunodeficiency
virus-infected macaques. J Virol. 2007; 81:8621–8633. [PubMed: 17537860]
53. Nishimura Y, Shingai M, Willey R, et al. Generation of the pathogenic R5- tropic simian/human
immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol. 2010;
84:4769–4781. [PubMed: 20147396]
Arrildt et al. Page 13













54. Ren W, Tasca S, Zhuang K, et al. Different tempo and anatomic location of dual-tropic and X4
virus emergence in a model of R5 simian-human immunodeficiency virus infection. J Virol. 2010;
84:340–351. [PubMed: 19846515]
55. Ho SH, Shek L, Gettie A, et al. V3 loop-determined coreceptor preference dictates the dynamics of
CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. J Virol. 2005;
79:12296–12303. [PubMed: 16160156]
56. Nishimura Y, Igarashi T, Donau OK, et al. Highly pathogenic SHIVs and SIVs target different
CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl
Acad Sci U S A. 2004; 101:12324–12329. [PubMed: 15297611]
57. Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage
tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A. 2006;
103:15160–15165. [PubMed: 17015824]
58. Dunfee RL, Thomas ER, Wang J, et al. Loss of the N-linked glycosylation site at position 386 in
the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
Virology. 2007; 367:222–234. [PubMed: 17599380]
59. Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency
virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol. 2005; 79:7959–
7966. [PubMed: 15956542]
60. Harrington PR, Schnell G, Letendre SL, et al. Cross-sectional characterization of HIV-1 env
compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009; 23:907–915.
[PubMed: 19414991]
61. Pillai SK, Pond SLK, Liu Y, et al. Genetic attributes of cerebrospinal fluidderived HIV-1 env.
Brain. 2006; 129:1872–1883. [PubMed: 16735456]
62. Ritola K, Robertson K, Fiscus SA, et al. Increased human immunodeficiency virus type 1 (HIV-1)
env compartmentalization in the presence of HIV-1-associated dementia. J Virol. 2005; 79:10830–
10834. [PubMed: 16051875]
63. Xu Y, Zhu H, Wilcox CK, et al. Blood monocytes harbor HIV type 1 strains with diversified
phenotypes including macrophage-specific CCR5 virus. J Infect Dis. 2008; 197:309–318.
[PubMed: 18173363] . This is a provocative report identifying virus in monocytes that have lost
the ability to replicate in T cells.
64. Li S, Juarez J, Alali M, et al. Persistent CCR5 utilization and enhanced macrophage tropism by
primary blood human immunodeficiency virus type1 isolates from advanced stages of disease and
comparison to tissuederived isolates. J Virol. 1999; 73:9741–9755. [PubMed: 10559284]
65. Sterjovski J, Roche M, Churchill MJ, et al. An altered and more efficient mechanism of CCR5
engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology. 2010;
404:269–278. [PubMed: 20570309]
66. Taylor BM, Foulke JS, Flinko R, et al. An alteration of human immunodeficiency virus gp41 leads
to reduced CCR5 dependence and CD4 independence. J Virol. 2008; 82:5460–5471. [PubMed:
18353949]
67. Peters PJ, Duenas-Decamp MJ, Sullivan WM, et al. Variation in HIV-I R5 macrophage-tropism
correlates with sensitivity to reagents that block envelope: CD4 interactions but not with
sensitivity to other entry inhibitors. Retrovirology. 2008; 5:5. [PubMed: 18205925]
68. Roche M, Jakobsen MR, Sterjovski J, et al. HIV-1 Escape from the CCR5 Antagonist Maraviroc
Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That
Attenuates Macrophage Tropism. J Virol. 2011; 85:4330–4342. [PubMed: 21345957]
69. Sterjovski J, Churchill MJ, Ellett A, et al. Asn 362 in gp120 contributes to enhanced fusogenicity
by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
Retrovirology. 2007; 4:89. [PubMed: 18076768]
70. Duenas-Decamp MJ, Peters P, Burton D, Clapham PR. Natural resistance of human
immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine
residue close to the CD4 binding loop. J Virol. 2008; 82:5807–5814. [PubMed: 18385254]
71. Dunfee RL, Thomas ER, Gabuzda D. Enhanced macrophage tropism of HIV in brain and
lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site
antibody b12. Retrovirology. 2009; 6:69. [PubMed: 19619305]
Arrildt et al. Page 14













72. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR. Determinants flanking the CD4 binding
loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J
Virol. 2009; 83:2575–2583. [PubMed: 19129457]
73. Zhuang K, Finzi A, Tasca S, et al. Adoption of an "Open" Envelope Conformation Facilitating
CD4 Binding and Structural Remodeling Precedes Coreceptor Switch in R5 SHIV-Infected
Macaques. Plos One. 2011; 6:e21350. [PubMed: 21760891] . This paper reports a new cell line
where CD4 and CCR5 are under control of a regulatable promoters, allowing quantitative
assessment of the need for these receptors in entry.
74. Johnston SH, Lobritz MA, Nguyen S, et al. A quantitative affinity-profiling system that reveals
distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian
immunodeficiency virus strains. J Virol. 2009; 83:11016–11026. [PubMed: 19692480]
75. Duenas-Decamp MJ, Clapham PR. HIV-1 gp120 Determinants Proximal to the CD4 Binding Site
Shift Protective Glycans That Are Targeted by Monoclonal Antibody 2G12. J Virol. 2010;
84:9608–9612. [PubMed: 20610714]
76. Richards KH, Aasa-Chapman MMI, McKnight A, Clapham PR. Modulation of HIV-1
macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.
Retrovirology. 2010; 7:48. [PubMed: 20507591]
77. Musich T, Peters PJ, Duenas-Decamp MJ, et al. A Conserved Determinant in the V1 Loop of
HIV-1 Modulates the V3 Loop To Prime Low CD4 Use and Macrophage Infection. J Virol. 2011;
85:2397–2405. [PubMed: 21159865]
78. Walter BL, Wehrly K, Swanstrom R, et al. Role of low CD4 levels in the influence of human
immunodeficiency virus type 1 envelope V2 and V2 regions on entry and spread in macrophages.
J Virol. 2005; 79:4828–4837. [PubMed: 15795268]
79. Cashin K, Roche M, Sterjovski J, et al. Alternative coreceptor requirements for efficient CCR5-
and CXCR4-mediated HIV-1 entry into macrophages. J Virol. In press.
80. Ghaffari G, Tuttle DL, Briggs D, et al. Complex determinants in human immunodeficiency virus
type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. J Virol. 2005;
79:13250–13261. [PubMed: 16227248]
81. Auffray C, Sieweke MH, Geissmann F. Blood Monocytes: Development, Heterogeneity, and
Relationship with Dendritic Cells. Annu Rev Immunol. 2009; 27:669–692. [PubMed: 19132917]
82. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte
subsets. J Leuk Biol. 2001; 69:11–20.
83. Ellery PJ, Tippett E, Chiu YL, et al. The CD16(+) monocyte subset is more permissive to infection
and preferentially harbors HIV-1 in vivo. J Immunol. 2007; 178:6581–6589. [PubMed: 17475889]
84. Wong KL, Tai JJ, Wong WC, et al. Gene expression profiling reveals the defining features of the
classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011; 118:e16–e31.
[PubMed: 21653326]
85. Crowe S, Zhu TF, Muller WA. The contribution of monocyte infection and trafficking to viral
persistence, and maintenance of the viral reservoir in HIV infection. J Leuk Biol. 2003; 74:635–
641.
86. Fogg DK, Sibon C, Miled C, et al. A clonogenic bone marrow progenitor specific for macrophages
and dendritic cells. Science. 2006; 311:83–87. [PubMed: 16322423]
87. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in
blood. Blood. 2010; 116:E74–E80. [PubMed: 20628149]
88. Naif HM, Li S, Alali M, et al. CCR5 expression correlates with susceptibility of maturing
monocytes to human immunodeficiency virus type 1 infection. J Virol. 1998; 72:830–836.
[PubMed: 9420295]
89. Sonza S, Maerz A, Uren S, et al. Susceptibility of Human Monocytes to HIV Type 1 Infection in
Vitro Is Not Dependent on Their Level of CD4 Expression. AIDS Res Hum Retroviruses. 1995;
11:769–776. [PubMed: 7546902]
90. Dong C, Kwas C, Wu L. Transcriptional restriction of human immunodeficiency virus type 1 gene
expression in undifferentiated primary monocytes. J Virol. 2009; 83:3518–3527. [PubMed:
19211771]
Arrildt et al. Page 15













91. Sung T-L, Rice AP. miR-198 Inhibits HIV-1 Gene Expression and Replication in Monocytes and
Its Mechanism of Action Appears To Involve Repression of Cyclin T1. Plos Pathog. 2009;
5:e1000263. [PubMed: 19148268]
92. Lewin SR, Lambert P, Deacon NJ, et al. Constitutive expression of p50 homodimer in freshly
isolated human monocytes decreases in vitro and in vivo differentiation: A possible mechanism
influencing human immunodeficiency virus replication in monocytes and mature macrophages. J
Virol. 1997; 71:2114–2119. [PubMed: 9032344]
93. Arfi V, Riviere L, Jarrosson-Wuilleme L, et al. Characterization of the early steps of infection of
primary blood monocytes by human immunodeficiency virus type 1. J Virol. 2008; 82:6557–6565.
[PubMed: 18417568]
94. Meuret G, Bammert J, Hoffmann G. Kinetics of Human Monocytopoiesis. Blood. 1974; 44:801–
816. [PubMed: 4429800]
95. Zhu TF, Muthui D, Holte S, et al. Evidence for human immunodeficiency virus type 1 replication
in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly
active antiretroviral therapy. J Virol. 2002; 76:707–716. [PubMed: 11752161]
96. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replicationcompetent, non-latent
HIV-1 in patients on highly active antiretroviral therapy. AIDS. 2001; 15:17–22. [PubMed:
11192864] .
97. Riddick NE, Hermann EA, Loftin LM, et al. A novel CCR5 mutation common in sooty mangabeys
reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in
vivo. PLoS Pathog. 2010; 6:e1001064. [PubMed: 20865163]
98. Dumonceaux J, Nisole S, Chanel C, et al. Spontaneous mutations in the env gene of the human
immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry
phenotype. J Virol. 1998; 72:512–519. [PubMed: 9420253]
99. Haim H, Strack B, Kassa A, et al. Contribution of Intrinsic Reactivity of the HIV-1 Envelope
Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity. Plos Pathog. 2011;
7:e1002101. [PubMed: 21731494]
100. Hoffman TL, LaBranche CC, Zhang WT, et al. Stable exposure of the coreceptor-binding site in a
CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A. 1999; 96:6359–6364.
[PubMed: 10339592]
101. Kolchinsky P, Mirzabekov T, Farzan M, et al. Adaptation of a CCR5-using, primary human
immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol. 1999; 73:8120–
8126. [PubMed: 10482561]
102. Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in
kidney epithelium of patients with HIV-associated nephropathy. Nature Medicine. 2002; 8:522–
526.
103. Edwards TG, Hoffman TL, Baribaud F, et al. Relationships between CD4 independence,
neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency
virus type 1 envelope protein. J Virol. 2001; 75:5230–5239. [PubMed: 11333905]
104. Eitner F, Cui Y, Hudkins KL, et al. Chemokine receptor CCR5 and CXCR4 expression in HIV-
associated kidney disease. Journal of the American Society of Nephrology. 2000; 11:856–867.
[PubMed: 10770963]
105. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of
HIV-1 infection. Journal of the American Society of Nephrology. 2000; 11:2079–2087.
[PubMed: 11053484]
Arrildt et al. Page 16













Figure 1. Compartmentalization and Replication in Alternative Cell Populations
Compartmentalization has been frequently detected in the CNS of people with HIV-
associated neurological disorders and there is evidence that compartmentalization can occur
in other anatomical sites. Although a contribution of viral replication to pathogenesis in the
CNS is well established, effects in other compartments will require further study.
Arrildt et al. Page 17









































































































































































































































































































































































Curr HIV/AIDS Rep. Author manuscript; available in PMC 2013 May 20.
